Vaccinia Immune Globulin Intravenous (Human)
Vaccinia Immune Globulin Intravenous (Human) ("VIG") is Cangene's first biodefense product to be licensed by the U.S. Food & Drug Administration (“FDA”) and Health Canada. VIG contains specific antibodies to the Vaccinia virus (the virus used to make smallpox vaccine). VIG may be included as a component of national biodefense programs.
Cangene developed this product under contract to the U.S. government and has supplied the product to the U.S. Strategic National Stockpile. Other governments have also purchased VIG from Cangene.